DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Phase 4

Completed

Conditions: ADHD

First Posted Date: 2005-09-16

Last Posted Date: 2010-07-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT00181675

Locations: 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States

Effect of Propranolol on Preventing Posttraumatic Stress Disorder

Phase 4

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: Propranolol
Drug: Placebo

First Posted Date: 2005-09-12

Last Posted Date: 2017-04-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 43

Registration Number: NCT00158262

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

First Posted Date: 2005-09-12

Last Posted Date: 2008-01-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 83

Registration Number: NCT00157560

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2005-09-12

Last Posted Date: 2008-05-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 95

Registration Number: NCT00157547

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: GM-CSF, sargramostim

First Posted Date: 2005-09-12

Last Posted Date: 2017-05-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 72

Registration Number: NCT00157573

Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

Phase 3

Completed

Conditions: Somatoform Disorders
Anxiety Disorders

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2005-09-08

Last Posted Date: 2017-12-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 100

Registration Number: NCT00149799

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: ET 743

First Posted Date: 2005-09-07

Last Posted Date: 2013-01-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT00147212

Locations: 🇺🇸
Masachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Bevacizumab

First Posted Date: 2005-09-02

Last Posted Date: 2014-03-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 33

Registration Number: NCT00142467

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Cetuximab

First Posted Date: 2005-09-02

Last Posted Date: 2014-03-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00142428

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer
Gallbladder Adenocarcinoma

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Drug: Bevacizumab
Procedure: Radiation therapy

First Posted Date: 2005-09-02

Last Posted Date: 2018-04-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT00142480

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy